

# AXL Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7602d

### **Product Information**

Application Primary Accession Reactivity Host Clonality	IHC-P, FC, WB, E <u>P30530</u> Human Rabbit Polyclonal Pabbit IgG
Isotype	Rabbit IgG
Clone Names	RB17700
Calculated MW	98337

## **Additional Information**

Gene ID	558
Other Names	Tyrosine-protein kinase receptor UFO, AXL oncogene, AXL, UFO
Target/Specificity	This AXL antibody is generated from rabbits immunized with a his tag recombinant protein of human AXL.
Dilution	IHC-P~~1:100~500 FC~~1:10~50 WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	AXL Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**

Name	AXL
Synonyms	UFO
Function	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface

	induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Highly expressed in metastatic colon tumors. Expressed in primary colon tumors. Weakly expressed in normal colon tissue.

### Background

AXL, a member of the AXL/UFO subfamily of Tyr protein kinases, may function as a signal transducer between specific cell types of mesodermal origin. This Type I membrane protein has transforming potential in patients with chronic myeloproliferative disorder or chronic myelocytic leukemia. The protein contains 2 putative fibronectin type III domains and 2 putative immunoglobulin-like C2-type domains.

### References

Lee, S.T., et al., Oncogene 8(12):3403-3410 (1993). Janssen, J.W., et al., Oncogene 6(11):2113-2120 (1991). O'Bryan, J.P., et al., Mol. Cell. Biol. 11(10):5016-5031 (1991). Partanen, J., et al., Proc. Natl. Acad. Sci. U.S.A. 87(22):8913-8917 (1990).

#### Images



All lanes : Anti-AXL Antibody at 1:2000 dilution Lane 1: Hela whole cell lysate Lane 2: DU145 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 98 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Formalin-fixed and paraffin-embedded human colon carcinoma with AXL Antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



Flow cytometric analysis of WiDr cells using AXL Antibody(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.